<DOC>
	<DOCNO>NCT01491854</DOCNO>
	<brief_summary>This study perform part Marketing Authorisation Holder 's post-marketing pharmacovigilance plan investigate long-term safety , particular diabetogenic potential immunogenicity rhGH therapy short child bear small gestational age ( SGA ) .</brief_summary>
	<brief_title>Long-term Safety Follow-up After Growth Hormone Treatment Short Children Born Small Gestational Age</brief_title>
	<detailed_description>The purpose study 1. monitor short child bear SGA treat growth hormone study EP00-401 development diabetes 10 year termination growth hormone treatment 2. report incidence anti-rhGH antibody E. coli host cell peptide ( HCP ) antibody ( ABs ) 6 month termination GH treatment .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<criteria>All patient fulfil diagnosis SGA , participate study EP00401 , receive least one dose study medication Written inform consent patient ( child read and/ understand ) and/or parent legal guardian Patients unwilling and/or parents/guardians capable ensure compliance provision study protocol</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Long-term</keyword>
	<keyword>safety</keyword>
	<keyword>follow-up</keyword>
	<keyword>growth hormone treatment</keyword>
	<keyword>short child</keyword>
	<keyword>Small Gestational Age</keyword>
	<keyword>Somatropin</keyword>
</DOC>